RosettaLigand is premiere software for predicting how a protein and a small molecule interact. Benchmark studies demonstrate that 70% of the top scoring RosettaLigand predicted interfaces are within 2Å RMSD from the crystal structure [1]. The latest release of Rosetta ligand software includes many new features, such as (1) docking of multiple ligands simultaneously, (2) representing ligands as fragments for greater flexibility, (3) redesign of the interface during docking, and (4) an XML script based interface that gives the user full control of the ligand docking protocol.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749076 | PMC |
| http://dx.doi.org/10.1007/978-1-61779-465-0_10 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Automated identification of small molecules in cryo-electron microscopy data with density- and energy-guided evaluation.
bioRxiv
November 2024
Department of Biochemistry, University of Washington, Seattle, WA, USA.
Methodological improvements in cryo-electron microscopy (cryoEM) have made it a useful tool in ligand-bound structure determination for biology and drug design. However, determining the conformation and identity of bound ligands is still challenging at the resolutions typical for cryoEM. Automated methods can aid in ligand conformational modeling, but current ligand identification tools - developed for X-ray crystallography data - perform poorly at resolutions common for cryoEM.
View Article and Find Full Text PDFAnalysis of EGFR binding hotspots for design of new EGFR inhibitory biologics.
Protein Sci
October 2024
Department of Chemistry, Vanderbilt University, Nashville, Tennessee, USA.
The epidermal growth factor (EGF) receptor (EGFR) is activated by the binding of one of seven EGF-like ligands to its ectodomain. Ligand binding results in EGFR dimerization and stabilization of the active receptor conformation subsequently leading to activation of downstream signaling. Aberrant activation of EGFR contributes to cancer progression through EGFR overexpression/amplification, modulation of its positive and negative regulators, and/or activating mutations within EGFR.
View Article and Find Full Text PDFImproved Prediction of Stabilizing Mutations in Proteins by Incorporation of Mutational Effects on Ligand Binding.
Proteins
January 2025
Molecular Biophysics Unit (MBU), Indian Institute of Science, Bengaluru, India.
While many computational methods accurately predict destabilizing mutations, identifying stabilizing mutations has remained a challenge, because of their relative rarity. We tested ΔΔG predictions from computational predictors such as Rosetta, ThermoMPNN, RaSP, and DeepDDG, using 82 mutants of the bacterial toxin CcdB as a test case. On this dataset, the best computational predictor is ThermoMPNN, which identifies stabilizing mutations with a precision of 68%.
View Article and Find Full Text PDFCharacterization of a Novel Monoclonal Antibody with High Affinity and Specificity against Aflatoxins: A Discovery from Rosetta Antibody-Ligand Computational Simulation.
J Chem Inf Model
September 2024
National Center of Meat Quality & Safety Control, College of Food Science and Technology, Nanjing Agricultural University, Nanjing 210095, China.
Aflatoxin B1 (AFB) accumulates in crops, where it poses a threat to human health. To detect AFB, anti-AFB monoclonal antibodies have been developed and are widely used. While the sensitivity and specificity of these antibodies have been extensively studied, information regarding the atomic-level docking of AFB (and its derivatives) with these antibodies is limited.
View Article and Find Full Text PDFToward high-resolution modeling of small molecule-ion channel interactions.
Front Pharmacol
June 2024
Department of Physiology and Membrane Biology, University of California, Davis, Davis, CA, United States.
Ion channels are critical drug targets for a range of pathologies, such as epilepsy, pain, itch, autoimmunity, and cardiac arrhythmias. To develop effective and safe therapeutics, it is necessary to design small molecules with high potency and selectivity for specific ion channel subtypes. There has been increasing implementation of structure-guided drug design for the development of small molecules targeting ion channels.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!